Table 1.
Baseline characteristic information of participants
| Variable |
Immunomodulator
group |
Immunosupp
ressive group |
Healthy people
(control group) |
P |
Statistical
test |
|---|---|---|---|---|---|
| Age (year) (mean ± SD) | 38.84 ± 8.29 | 39.21 ± 8.55 | 40.23 ± 9.03 | 0.740 | ANOVA |
| Duration of MS diagnosis (months) (mean ± SD) |
35.28 ± 22.73 | 48.81 ± 22.17 | - | 0.006 | T |
| Duration of previous MS treatments (months) (mean ± SD) |
14.82 ± 5.65 | 16.86 ± 9.95 | - | 0.001 | T |
| Duration of current MS Treatments (months) (mean ± SD) |
26.35 ± 17.24 | 18.91 ± 15.41 | - | 0.037 | T |
| EDSS | 1.13 ± 0.90 | 3.89 ± 0.44 | - | 0.001 | T |
MS: Multiple Sclerosis; EDSS: Expanded Disability Status Scale